Last reviewed · How we verify
SEVABERTINIB
Sevabertinib inhibits HER2 and EGFR phosphorylation, blocking downstream signaling and cancer cell proliferation.
At a glance
| Generic name | SEVABERTINIB |
|---|---|
| Target | HER2, EGFR |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Sevabertinib works by inhibiting the activity of HER2 and EGFR receptors. This inhibition stops the phosphorylation of these receptors, which in turn blocks the downstream signaling pathways that promote cancer cell growth and proliferation. It is particularly effective in cancer cells with HER2 alterations or mutations.
Approved indications
Common side effects
- diarrhea
- stomatitis
- nausea
- vomiting
- abdominal pain
- rash
- paronychia
- dry skin
- pruritus
- decreased appetite
- weight decreased
Drug interactions
- Strong CYP3A Inhibitors
- Moderate CYP3A Inhibitors
- Strong and Moderate CYP3A Inducers
- Certain CYP3A Substrates
- Certain P-gp Substrates
Key clinical trials
- A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) (PHASE2)
- A Study to Learn More About How Well Sevabertinib (BAY 2927088) Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) (PHASE3)
- Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation
- A Study Evaluating How Moderate Liver Impairment Affects the Absorption, Distribution, Metabolism, and Elimination of Sevabertinib After a Single Oral Dose (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SEVABERTINIB CI brief — competitive landscape report
- SEVABERTINIB updates RSS · CI watch RSS